Sandrine Oziel-Taieb: Hematological Toxicity Management During Lu-Dotatate
Sandrine Oziel-Taieb, Medical Oncologist at the Paoli Calmettes Institute, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in EJNMMI, adding:
“Our national survey on hematological toxicity management during Lu Dotatate is now published in the European Journal of Nuclear Medicine and Molecular Imaging.
The LutaVire survey, conducted under the auspices the GTE, SFMN and endocan renaten network, highlights substantial real-world heterogeneity in how clinicians manage thrombocytopenia and long term bone marrow safety during PRRT, and underscores the need for harmonized, individualized monitoring guidelines.
Thank you to all 40 expert physicians who contributed, and to my co autors Magalie Haissaguerre, Catherine Ansquer, Emmanuel Deshayes, and Ghoufrane Tlili.”
Title: Managing hematological toxicity in Lu-DOTATATE for NET patients: a national survey from the French group of endocrine tumors (GTE) on the clinical need for harmonized monitoring strategies
Authors: S. Oziel-Taieb, C. Ansquer, G. Tlili, E. Deshayes, M. Haissaguerre
Stay updated on all scienntific advances with Hemostasis Today.
-
Sep 5, 2026, 16:28Jon Douglas: Imperial College London Review Maps Key Pathways in Autoimmune Thrombosis
-
Sep 5, 2026, 16:21Kelly Anderson: Bilateral Foot Pain and Purple Toes – Spotting Vascular Complications in Polycythemia Vera
-
Sep 5, 2026, 16:16Hazem Abosheaishaa: Beta-Blocker Selection Matters – Multi-Institutional Cohort Insights on PVT and Survival in Cirrhosis
-
Sep 5, 2026, 16:08Indre Ceponiene: Major Gaps in Secondary Cardiovascular Prevention Across Europe
-
Sep 5, 2026, 16:03W. Alberto Sifuentes Giraldo: Why Obstetric Cases Are Missed Under 2023 ACR/EULAR APS Criteria
-
Sep 5, 2026, 15:58Srikanth Nalla: A Case of Saddle Pulmonary Embolism
-
Sep 5, 2026, 15:55COPD-specific Pulmonary Embolism Diagnostic Strategy – Thrombosis and Haemostasis
-
Sep 5, 2026, 15:41Sam Tsimikas on Lp(a) HORIZON Topline Results – What Missed Endpoints Mean for Cardiovascular Risk
-
Sep 5, 2026, 15:32Stefano Garzon: SELUTION DeNovo HBR – Weren’t HBR Patients Supposed to Bleed More with DES?